Home › Glioma › North Carolina
Pag-aaral pangklinika para sa Glioma sa North Carolina
16 pag-aaral para sa Glioma ang naghahanap ng mga kalahok sa mga site sa North Carolina.
Mga Lungsod sa North Carolina
Opisyal na teksto ng pag-aaral (English)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Novant Health Presbyterian Medical Center, Charlotte
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
Nagre-recruitPhase 1/2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Duke University Medical Center, Durham
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
Nagre-recruitObservasyonal na pag-aaral
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT05303519ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05609994PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Duke Cancer Center, Durham
Nagre-recruitPhase 2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05096481MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05212272A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 2
Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT06177964Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update May 29, 2026 · NCT05843253Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Duke University, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06126744A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Duke University Health System, Durham
Nagre-recruitMaagang Phase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT04655404Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.